EKF DIAGNOSTICS HOLDINGS PLC

Remuneration Information • Sep 16, 2025

National Storage Mechanism | Additional information

RNS Number : 4126Z

EKF Diagnostics Holdings PLC

16 September 2025

EKF Diagnostics Holdings plc

("EKF" or "the Company")

Long Term Incentive Plan

The Board recognises the importance of incentivising and rewarding the performance of its key executives, and having considered the views of certain of its shareholders, recently tasked the remuneration committee to recommend to the Board an appropriate long term incentive plan (" LTIP ") for its senior executives.

The Board, following the recommendation of the remuneration committee and after consulting its advisers, has today made the following award (the "Award") to Gavin Jones (Chief Executive Officer) under the Company's newly established LTIP that was adopted on 9 September 2025:

Individual	Position	Type of Award	Number of ordinary shares subject to LTIP award
Gavin Jones	Chief Executive Officer	LTIP award - nominal cost option	500,000

The Award has a performance period from the grant date to the third anniversary of the grant date and are subject to the following performance criteria.

The Award shall vest on a sliding scale depending on the total percentage growth of Adjusted EBITDA per share over the Performance Period, as follows:

(i)            Growth of 25% or higher: 100% of the Award vests.

(ii)           Between 10% and 25% growth: Vesting shall occur on a straight-line basis between 25% and 100%.

(iii)          10% growth: 25% of the Award vests; or

(iv)         Below 10% growth: 0% of the Award vests.

Comment from the Chair of the Remuneration committee, Jenny Winter:

"It is important that Gavin is rewarded in a way which links his performance with shareholder value creation. I am satisfied that these incentivisation arrangements achieve that objective."

EKF Diagnostics Holdings plc		www.ekfdiagnostics.com
Julian Baines, Executive Chair		via Walbrook PR
Gavin Jones, Chief Executive Officer
Stephen Young, Chief Financial Officer
Singer Capital Markets (Nominated Adviser & Broker)		Tel: +44 (0)20 7496 3000
Phil Davies / Oliver Platts
Walbrook PR Limited	Tel: +44 (0)20 7933 8780 or [email protected]
Paul McManus / Alice Woodings	Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

About EKF Diagnostics Holdings plc  (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

·    Point-of-Care analysers in the key areas of Hematology and Diabetes.

·    Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Gavin Jones
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	EKF Diagnostics Holdings plc
b)	LEI	213800DXTF3EAUK1AR05
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 1 pence each
Identification code	GB0031509804
b)	Nature of the transaction	Grant of options over ordinary shares pursuant to the Company's LTIP
c)	Price(s) and volume(s)
		Price(s)	Volume(s)
		1p	500,000
d)	Aggregated information
- Aggregated volume	n/a
- Price
e)	Date of the transaction	16 September 2025
f)	Place of the transaction	Outside a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFIDASIELIE